Piraye Beim
About Piraye Beim
Founder & CEO of Celmatix
Piraye Yurttas Beim is the Founder and CEO of Celmatix. With over 20 years of experience in women's health innovation, she has led the company in pioneering advancements in the field. Her leadership at Celmatix has been instrumental in developing diagnostics and digital health products aimed at improving women's health outcomes.
Education and Academic Background
Piraye Yurttas Beim completed her PhD work at Cornell (Weill, NYC) and Memorial Sloan Kettering Cancer Center, where she focused on precision medicine in oncology. She further advanced her academic career by completing a post-doctoral fellowship at the University of Cambridge (UK), concentrating on mammalian reproduction. Her academic expertise has significantly contributed to her groundbreaking work in women's health.
Innovation in Women's Health
Piraye Yurttas Beim has been at the forefront of breakthroughs in women's health, particularly in decoding the genomic drivers of ovarian function and health. As the primary inventor of Celmatix's innovations, her work includes the development of the AMHR2 agonist and antagonist programs, which have potential applications in women's reproductive health.
Membership and Recognitions
Piraye Yurttas Beim's contributions to entrepreneurship and women's health have been widely recognized. She is a member of the Aspen Global Leadership Network and has been honored with multiple prestigious accolades, including being named to Crain's 40 Under 40 and Notable Women in Tech. She has also received recognition from Goldman Sachs as one of the Most Intriguing Entrepreneurs and was listed among Fortune’s Top 15 founders disrupting their industries. Rock Health awarded her the Disruptive Founder of the Year.